Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Equity Ratio (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Equity Ratio readings, the most recent being 0.88 for Q1 2026.

  • Quarterly Equity Ratio rose 21.05% to 0.88 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.88 through Mar 2026, up 21.05% year-over-year, with the annual reading at 0.87 for FY2025, 16.94% up from the prior year.
  • Equity Ratio hit 0.88 in Q1 2026 for Ovid Therapeutics, up from 0.87 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.88 in Q1 2026 and bottomed at 0.59 in Q1 2024.
  • Average Equity Ratio over 5 years is 0.78, with a median of 0.81 recorded in 2023.
  • The largest annual shift saw Equity Ratio fell 29.5% in 2024 before it increased 22.05% in 2025.
  • Ovid Therapeutics' Equity Ratio stood at 0.85 in 2022, then fell by 28.44% to 0.61 in 2023, then rose by 21.43% to 0.74 in 2024, then rose by 16.94% to 0.87 in 2025, then increased by 1.51% to 0.88 in 2026.
  • Per Business Quant, the three most recent readings for OVID's Equity Ratio are 0.88 (Q1 2026), 0.87 (Q4 2025), and 0.7 (Q3 2025).